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Abstract
Background—About half of the 5 million heart failure patients in the United States have diastolic
heart failure (clinical heart failure with normal or near normal ejection fraction). Except for
candesartan, no drugs have been tested in randomized clinical trials in these patients. Although
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digoxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis
Investigation Group ancillary trial, detailed findings from this important study has not been
previously published.
Methods and Results—Ambulatory chronic heart failure patients (N=988) with normal sinus
rhythm and ejection fraction >45% (median, 53%) from the US and Canada (1991–1993) were
randomly assigned to digoxin (n=492) or placebo (n=496). During 37 months of mean follow up,
the primary combined outcome of heart failure hospitalization or heart failure mortality was
experienced by 102 (21%) patients in the digoxin group and 119 (24%) patients in the placebo group
(hazard ratio=0.82; 95% confidence interval=0.63–1.07; p=0.136). Digoxin had no effect on all-
cause, or cause-specific mortality, or all-cause or cardiovascular hospitalization. Use of digoxin was
associated with a trend toward reduction in hospitalizations due to worsening heart failure (hazard
ratio=0.79; 95% confidence interval=0.59–1.04; p=0.094), but also a trend toward an increase in
hospitalizations for unstable angina (HR=1.37; 95% CI=0.99–1.91; p=0.061).
Conclusions—In ambulatory patients with mild to moderate diastolic heart failure and normal
sinus rhythm, receiving angiotensin-converting enzyme inhibitor and diuretics, digoxin had no effect
on natural history endpoints such as mortality and all-cause or cardiovascular hospitalizations.
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There are an estimated 5 million heart failure (HF) patients in the United States.1 About half
of these patients have diastolic HF, defined as clinical HF with normal or near normal left
ventricular ejection fraction (LVEF),2 and this group has substantial morbidity and mortality.
1, 3–6 Despite this high prevalence of diastolic HF, except for the Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved trial, these patients
have generally been excluded from randomized HF trials.7
Digitalis glycosides have been used in HF for over two centuries, are inexpensive, and have
been extensively studied in systolic HF.8 The role of digoxin in patients with diastolic HF was
evaluated in the Digitalis Investigation Group (DIG) ancillary trial, which was conducted in
parallel with the main DIG trial.9–12 The objective of the DIG ancillary trial was to assess the
effect of digoxin on the primary combined outcome of HF hospitalization or HF mortality. We
analyzed a public-use copy of the DIG dataset obtained from the National Heart, Lung, and




The DIG trial was a randomized clinical trial, sponsored by the NHLBI, the Department of
Veterans Affairs Cooperative Studies, and Glaxo Wellcome (who supplied the study drug,
Lanoxin, and placebo). The purpose of the DIG trial was to evaluate the effects of digoxin on
mortality and hospitalizations in ambulatory chronic HF patients with normal sinus rhythm.
10 HF patients with LVEF ≤45% (n=6,800) comprised the main trial whereas those with LVEF
>45% (n=988) were enrolled in an ancillary study conducted parallel to the main trial. The
design and results of the DIG trial have been previously reported.9, 10
Patients
In the DIG ancillary trial, 988 patients with LVEF >45% and normal sinus rhythm at baseline
were recruited from the U.S. (186 centers) and Canada (116 centers) between January 1991
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and August 1993. Patients received four different daily doses of digoxin or matching placebo
(0.125 mg, 0.25 mg, 0.375 mg, and 0.50 mg) based on age, sex, weight, and serum creatinine
levels.13 Over 90% of patients were receiving angiotensin converting enzyme (ACE) inhibitors
and over 80% were receiving diuretics.
Outcomes
The primary outcome in the ancillary DIG trial was the combined endpoint of HF
hospitalization or HF mortality. Vital status of all patients was collected up to December 31,
1995 and was 98.9% complete.14 DIG ancillary trial did not pre-specify other secondary
outcomes. However, we also studied other outcomes including all-cause and cardiovascular
mortality, and all-cause and cardiovascular hospitalizations. In addition, we also studied the
combined outcome of HF hospitalization or cardiovascular mortality, which was the primary
outcome in the CHARM-Preserved,7 the only other large randomized clinical trial in diastolic
HF. The cause of death or the primary diagnosis leading to hospitalization was classified by
DIG investigators who were blinded to the patient’s study-drug assignment.
Statistical Analysis
Kaplan–Meier analysis was used to construct survival plots, and a log-rank statistic was used
to compare the survival distributions in the two study groups. To compare the effects of digoxin
with that of placebo, we calculated hazard ratios (HR) and 95% confidence intervals (CI)
associated with primary and other outcomes using Cox proportional-hazards models.
Differences in the number of hospitalizations between groups were estimated using the
Wilcoxon rank-sum test. All analyses were repeated for outcomes at two years after
randomization. Because the effect of digoxin on outcomes was expected to be more marked
in the first two years after randomization, a separate analysis of the effect of digoxin during
this period was pre-specified in the DIG protocol.13 All analyses were performed on an
intention-to-treat basis with two-sided P values <0.05 considered significant using SPSS for
Windows version 13.0.1.
Role of the funding source
Several of the co-authors of the present report (J.L.F, M.G., M.W.R., and J.B.Y.) were
investigators in the DIG trial.
Statement of Responsibility
Statistical analyses were conducted by A.A. in collaboration with T.E.L. Fidelity of the raw
data was verified by Sean Coady at the NHLBI. The authors had full access to the data and




Baseline patient characteristics are presented in Table 1. Patients had a median age of 67 years,
41% were women, 14% were non-white, and 73% had LVEF =>50%. There were no significant
differences in baseline characteristics between the 492 patients randomly assigned to digoxin
and 496 patients assigned to placebo (Table 1).
Heart Failure Hospitalization or Heart Failure Mortality: The Primary Outcome
After a mean follow up of 37 months, 102 (21%) patients in the digoxin group and 119 (24%)
patients in the placebo group experienced the primary combined outcome of HF hospitalization
or HF mortality (HR when digoxin was compared with placebo, 0.82; 95% CI, 0.63 to 1.07;
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p, 0.136) (Figure 1a and Table 2), which is consistent with the main DIG report.10 During the
first two years of follow up after randomization, 67 (14%) patients in the digoxin group and
90 (18%) patients in the placebo group experienced the primary combined outcome (HR, 0.71;
95% CI, 0.52 to 0.98; p, 0.034) (Figure 1a and Table 2).
Heart Failure Hospitalization or Cardiovascular Mortality
Hospitalizations due to HF or deaths due to cardiovascular causes, the primary outcomes used
in the CHARM-Preserved trial, occurred in 142 (29%) patients in the digoxin group and 154
(31%) patients in the placebo group (HR, 0.88; 95% CI, 0.70 to 1.11; p, 0.269) (Figure 1b and
Table 2). At two years after randomization, compared with 113 (23%) patients in the placebo
group, 89 (18%) patients in the digoxin group experienced HF hospitalizations or
cardiovascular mortality (HR, 0.75; 95% CI, 0.57 to 0.99; p, 0.044) (Figure 1b and Table 2).
Effect of Digoxin on Mortality
There were 115 deaths from all causes in the digoxin group (23%) and 116 deaths in the placebo
group (23%) during the study (HR, 0.99; 95% CI, 0.76 to 1.28; p, 0.925) (Figure 2a and Table
2). There were 30 deaths due to HF among patients randomized to receive digoxin (6%) and
34 deaths (7%) from the same cause among patients randomized to receive placebo (HR, 0.88;
95% CI, 0.54 to 1.43; p, 0.598) (Figure 2b and Table 2). There was no difference in mortality
due to cardiovascular causes (81 in each group; HR, 1.00; 95% CI, 0.73 to 1.36; p, 0.978)
(Figure 2c and Table 2). Effects of digoxin on mortality from various causes at two years are
displayed in Figures 2a, 2b, and 2c, and Table 2.
Effect of Digoxin on Hospitalization
Hospitalization due to worsening HF occurred in 89 (18%) patients randomized to digoxin and
108 (22%) patients randomized to placebo (HR, 0.79; 95% CI, 0.59 to 1.04; p, 0.094) (Figure
3c and Table 3). During the first two-years of the study, 59 patients randomized to digoxin
(12%) and 86 patients randomized to placebo (17%) were hospitalized due to worsening of HF
(HR, 0.66; 95% CI, 0.47 to 0.91; p, 0.012) (Figure 3c and Table 3).
Hospital admissions due to cardiovascular causes occurred in 241 (49%) patients in the digoxin
group and 225 (45%) patients in the placebo group (HR, 1.10; 95% CI, 0.92 to 1.32; p, 0.301)
(Figure 3b and Table 3). There were no difference in all-cause hospitalizations between the
two groups (68% in the digoxin group and 67% in the placebo group; HR, 1.03; 95% CI, 0.89
to 1.20; p, 0.683) (Figure 3a and Table 3). Among patients who were hospitalized for all causes,
332 in the digoxin group had 985 (median, 2) total hospitalizations for all reasons combined
and 330 in the placebo group had 949 (median, 2) such hospitalizations (Wilcoxon test p,
0.811). The effects of digoxin on various causes of hospitalizations at the end of two years of
follow up are displayed in Figures 3a, 3b and 3c, and Table 3. Compared with 62 (13%) patients
in the placebo group, 82 (17%) patients in the digoxin group were hospitalized due to unstable
angina during the study period (HR, 1.37; 95% CI, 0.99 to 1.91; p, 0.061; Table 3). The effect
of digoxin on hospitalizations by various causes are displayed in Table 3.
Adherence to Study Drugs
The median daily dose of the study drug at randomization was 0.25 mg for both the digoxin
and placebo groups. Twelve months after randomization, 384 (78%) patients in the digoxin
group and 384 (77%) patients in the placebo group were still receiving the study drug. The
median daily dose of the study drug at 12 month was 0.25 mg for both treatment groups. Over
the entire follow-up period, study drug was discontinued in 323 (33%) patients, of which 159
(32%) were receiving digoxin and 164 (33%) were receiving placebo (p, 0.802). Compared
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with 53 (11%) patients receiving placebo, 32 (7%) patients receiving digoxin required
prescription of open-label digoxin for worsening heart failure or atrial fibrillation (p, 0.019).
Digoxin Toxicity
Overall, 66 (7%) patients were identified by study investigators to have suspected or confirmed
digoxin toxicity during routine follow up and 21 (2%) of these occurred during the first two
years after randomization. As anticipated, there were more cases of suspected digoxin toxicity
in the digoxin group (48 or 10%) than in the placebo group (18 or 4%; p <0.001). Respective
numbers of suspected digoxin toxicity during the first two years were: 15 (3.0%) in the digoxin
group and 6 (1%) in the placebo group (p =0.049). Among the total of 66 patients with suspected
or confirmed digoxin toxicity, only one patient was hospitalized for that reason.
Discussion
The results of the current analysis demonstrate that digoxin had no favorable effect on the
natural history of ambulatory patients with chronic mild to moderate diastolic HF and normal
sinus rhythm. Although the results of the DIG ancillary trial were briefly reported in the original
DIG publication,10 the results presented in the current analysis provide the first detailed
analyses regarding use of digoxin in diastolic HF.
Clinical Importance
These findings are important for several reasons. Diastolic HF comprises up to 50% of all HF
patients, and most of these patients are older adults.3–6 Furthermore, with the population aging,
the prevalence of diastolic HF is projected to increase disproportionately in the coming decades.
Despite better survival compared to patients with systolic HF, older adults with diastolic HF
suffer from multiple morbidities and frequent hospitalizations.15, 16 However, diastolic HF
patients have traditionally been excluded from clinical HF trials; thus, there are few evidence-
based recommendations for these patients.17 Therefore, despite the age of the dataset used in
our analysis, the results of the current analysis have contemporary clinical relevance.
Effect of Digoxin on Heart Failure Hospitalization
The effect of digoxin on HF hospitalization in the ancillary DIG trial, though not significant,
is comparable to its effect in the main DIG trial and the effect of candesartan in the CHARM-
Preserved trial.7, 10 The magnitude of digoxin-associated reduction in HF hospitalization
observed in our analysis (HR=0.79; 95% CI=0.59 to 1.04) is similar to those observed in the
main DIG trial (HR=0.72; 95% CI=0.66 to 0.79)10 and the CHARM preserved trial (HR=0.85;
95% CI=0.72 to 0.1.01).7 The lack of statistical significance of the effects of digoxin in the
ancillary DIG trial is possibly due to small sample size (N=988 in the ancillary DIG trial, about
seven times smaller than N=6800 in the main DIG trial and over three times smaller than
N=3023 in the CHARM-Preserved trial). In addition, over 75% of participants in the ancillary
DIG trial had NYHA class I–II symptoms. Hospitalization due to worsening HF was much
lower among these patients than would be expected in diastolic HF patients in clinical practice.
16, 18 These relatively low event rates suggest that a larger study or one involving patients at
higher risk, such as those with more advanced symptoms, age, or m morbidities, may have
resulted in a greater reduction in the primary endpoint by digoxin. Despite the statistical
significance of the protocol pre-specified two-year outcomes, and the fact that it was the basis
of Food and Drug Administration approval of digoxin for use in HF, the results of the post-
hoc analyses of two-year outcomes should be interpreted with caution. This is particularly
important as digoxin had no favorable effect on the natural history of patients with HF and
normal or near normal LVEF.
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An unanticipated finding of the current analysis is that digoxin use was associated with
increased risk of hospitalization due to unstable angina, which offset the reduction in HF
hospitalization, resulting in no effect on cardiovascular hospitalizations. It is possible that the
amount of viable ischemic myocardium in diastolic HF is a larger than that in systolic HF.
However, the increased incidence unstable angina did not translate into increased myocardial
infarction or mortality.
Comparison with CHARM-Preserved Trial
In the CHARM-Preserved trial (N=3,023), at 37 months of median follow up, hospitalizations
due to HF or deaths due to cardiovascular causes, the primary outcomes of that trial, occurred
in 333 (22%) patients in the candesartan group and 366 (24%) patients in the placebo group
(HR, 0.89; 95% CI, 0.77 to 1.03; p = 0.118).7 In the DIG ancillary trial, on the other hand,
during a similar follow up (median, 39 months), 142 (29%) patients in the digoxin group and
154 (31%) patients in the placebo group experienced the same outcomes (HR, 0.88; 95% CI,
0.70 to 1.11; p, 0.269) (Figure 1, bottom panel and Table 2).
The primary reason for discontinuation of study drug in CHARM-Preserved was drug-related
adverse events, including hypotension, hyperkalemia, or abnormal laboratory values, such as
increase in creatinine, which was noted in 18% of patients in the candesartan group (versus
14% in the placebo group; p, 0.001).7 In contrast, the primary reason for discontinuation of
study drug in the DIG trial was the use of open-label digoxin due to worsening HF.10, 19
Although 66 (7%) patients were identified to have suspected or confirmed digoxin toxicity,
only one of these patients was hospitalized.
Implication for Future Research in Diastolic Heart Failure
Among diastolic HF patients in the DIG trial who received placebo, only 6% patients died from
HF, 17% from cardiovascular causes (11% in CHARM-Preserved),7 and overall mortality was
23%. In contrast, among systolic HF patients receiving placebo, 13% patients died from HF,
30% died from cardiovascular causes, and 35% from all causes combined.10 The low HF
mortality in diastolic HF should be taken into consideration in planning future clinical trials.
15
Clinical Implications: Role of Digoxin in Diastolic Heart Failure
Digitalis is the oldest and one of the least expensive drugs for the management of HF. Digoxin
has been historically thought to be contraindicated in patients with diastolic HF, often based
on anecdotal reports or non- randomized studies12, 20 The exact mechanistic explanation of
how digoxin may exert any potential beneficial effect in diastolic HF (as suggested by the trend
in HF hospitalization reduction) is not clearly understood. Although digoxin appears to
improve the active energy-dependent early myocardial diastolic function,6, 21 this has not been
well studied.12, 22 The effects of digoxin in diastolic HF may be related to its favorable effects
on neurohormonal profile.17, 23 It is now known that as in systolic HF, neurohormonal
activation is also present in diastolic HF and may contribute to disease progression.24, 25
Recent evidence suggests that digitalis glycosides may reduce sympathetic neurohormonal
activity by sensitizing cardiac baroreceptors,26 and suppress renin-angiotensin-aldosterone
system and reduce renal tubular reabsorption of sodium by inhibiting sodium-potassium
ATPase in the kidneys.27, 28 The trend toward increase in hospitalization for unstable angina
may be related to reported though not well studied effects of digoxin on platelet and endothelial
cell activation.29
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In ambulatory patients with chronic mild to moderate diastolic HF and normal sinus rhythm,
receiving ACE inhibitors and diuretics, digoxin use was not associated with any effect on total,
cardiovascular or HF mortality, or total or cardiovascular hospitalizations.
Clinicians Perspective
Diastolic heart failure (HF), defined as clinical HF with normal or near normal left ventricular
ejection fraction (LVEF) is common and associated with substantial morbidity and mortality.
Except for candesartan in the CHARM-Preserved (LVEF>40%), irbesartan in the ongoing I-
PRESERVE (LVEF≥45%), and digoxin in the Digitalis Investigation Group (DIG) ancillary
trials, no other drugs have been tested in these patients in randomized trials. The current study
reports the detailed analysis of the DIG ancillary trial in which 988 diastolic HF (LVEF>45%)
patients in normal sinus rhythm were randomized to receive digoxin or placebo. At 37-month
mean follow up, patients receiving digoxin had an 18% lower risk of HF hospitalization or HF
mortality, the primary outcome of the study, which was not statistically significant. The effect
of digoxin on HF hospitalization or cardiovascular mortality (the primary outcome of CHARM-
Preserved), was similar to that of candesartan in CHARM-Preserved (12% and 11% on-
significant reductions, respectively). The magnitude of the effect of digoxin on HF
hospitalization (21% non-significant reduction; p=0.094) was similar its effect in systolic HF
(a 28% significant reduction; p<0.001) and the effect of candesartan in CHARM-Preserved (a
15% non-significant reduction; p=0.072). An unexpected finding was that digoxin use was
associated with a non-significant 37% increased risk of hospitalization due to unstable angina
(p=0.061). Digoxin had no effect on natural history endpoints such as mortality and all-cause
or cardiovascular hospitalizations. Digoxin is an old and inexpensive HF drugs which has been
extensively studied in systolic HF. However, little is known about the effect of digoxin in
diastolic HF. Currently digoxin is often avoided in diastolic HF based on anecdotal reports or
non-randomized studies. The results of this study suggest that although digoxin may reduce
HF admissions in ambulatory patients with chronic mild to moderate diastolic HF receiving
ACE inhibitors and diuretics, digoxin does not exert a net beneficial effect on mortality or all-
cause or cardiovascular hospitalizations.
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Kaplan-Meier plots for (a) primary combined outcome of hospitalization due to worsening
heart failure or mortality due to heart failure, and (b) combined outcome of hospitalization due
to worsening heart failure or mortality due to cardiovascular causes, in diastolic heart failure
patients randomized to receive digoxin or placebo (The number of patients at risk at each 12-
month interval is shown below the figure)
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Kaplan-Meier plots for mortality due to (a) all causes, (b) cardiovascular causes, and (c) heart
failure, in diastolic heart failure patients randomized to receive digoxin or placebo (The number
of patients at risk at each 12-month interval is shown below the figure)
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Kaplan-Meier plots for hospitalization due to (a) all causes, (b) cardiovascular causes, and (c)
worsening heart failure, in diastolic heart failure patients randomized to receive digoxin or
placebo (The number of patients at risk at each 12-month interval is shown below the figure)
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Table 1
Baseline patient characteristics by treatment group
Placebo (N=496) Digoxin (N=492)
Age (years), mean (±SD) 66.9 (±9.9) 66.7 (±10.7)
Ejection fraction (%), mean (±SD) 55.5 (±8.1) 55.4 (±8.2)
Serum creatinine (mg/dL), mean (±SD) 1.26 (±0.39) 1.25 (±0.39)
Estimated glomerular filtration rate (ml/min/1.73 sq. meter), mean (±SD) 61.1 (±19.8) 62.4 (±21.3)
Median duration of heart failure, months 15 16
% of patients
Age ≥ 65 years 64.5 63.2
Women 40.3 42.1
Non-whites 13.3 14.4
Estimated glomerular filtration rate <60 ml/min/1.73 sq. meter 52.0 48.0
Ejection fraction ≥ 0.50 74.4 71.1
Method of assessing ejection fraction
 Radionuclide ventriculography 67.9 70.3
 Two-dimensional echocardiography 27.2 25.6
 Contrast angiography 4.8 4.1
Cardiothoracic ratio >0.55 26.4 26.8












 Previous myocardial infarction 49.4 49.6
 Current angina 29.2 30.3
 Diabetes 30.2 27.4
 Hypertension 57.5 62.0
Previous digoxin use 36.3 34.1
Primary cause of heart failure
 Ischemic 56.5 56.3
 Non-ischemic 43.5 43.7
   Hypertensive 21.0 24.0
   Idiopathic 10.7 10.4
   Others‡ 11.9 9.3
Concomitant medications
 Non-potassium-sparing diuretics 77.0 75.0
 Potassium-sparing diuretics 8.3 7.7
 Angiotensin-converting enzyme inhibitors 86.1 86.4
 Nitrates 38.9 39.8
 Other vasodilators§ 1.4 1.2
Daily dose of study medication
 0.125 mg 22.6 22.4
 0.250 mg 68.3 66.7
 0.375 mg 7.7 10.4
 0.500 mg 1.4 0.6
†
The clinical signs or symptoms studied included râles, elevated jugular venous pressure, peripheral edema, dyspnea at rest or on exertion, orthopnea,
limitation of activity, S3 gallop, and radiologic evidence of pulmonary congestion.
‡
This category included valvular and alcohol-related causes of heart failure.
§
These drugs included clonidine hydrochloride, doxazosin mesylate, flosequinan, labetalol hydrochloride, minoxidil, prazosin hydrochloride, and terazosin
hydrochloride

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Circulation. Author manuscript; available in PMC 2009 January 18.
